Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA drug safety committee

This article was originally published in The Tan Sheet

Executive Summary

The first in a series of meetings held by the Drug Safety & Risk Management Advisory Committee will take place May 18 and 19 at the Holiday Inn in Silver Spring, Md., 8:30 am - 5 pm, according to an April 14 Federal Register notice. Panelists will consider the advantages and disadvantages of FDA's current risk assessment program and safety detection of marketed drugs, including "review and analysis" of spontaneous adverse events reports, drug use data, administrative data, epidemiologic and observational studies, clinical trials and active surveillance systems...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS098086

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel